WinzWorld的个人主页 - 老虎社区

WinzWorld

WinzWorld

暂无个人介绍

IP属地：未知

5关注

0粉丝

0主题

0勋章

2021-12-29

Thanks for sharing! 👍🏻

APPS Stock Alert: 7 Things to Know About the Google Deal Goosing Digital Turbine Shares Today<blockquote>应用程序股票提醒：有关Google交易Goosing Digital Turbine今日股价上涨的7件事</blockquote>

2021-12-24

Merry Christmas 🥂

抱歉，原内容已删除

2021-12-24

Watching this space closely 😬

How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?<blockquote>辉瑞的口服COVID-19药丸能带来多少收入？</blockquote>

2021-12-24

The risk of delisting is really an issue for me...not sure if should take the risk and exit as soon as the price hits my target 🤔

Nio is on watch with attractive buying opportunity called out by Deutsche Bank<blockquote>德意志银行呼吁蔚来有吸引力的买入机会，受到关注</blockquote>

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4097106422038760","uuid":"4097106422038760","gmtCreate":1634023048628,"gmtModify":1640141424618,"name":"WinzWorld","pinyin":"winzworld","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/f94c1af784ca5816fdcf61d311d21996","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":5,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.10.24","exceedPercentage":"80.49%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.09.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.02.26","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":696418210,"gmtCreate":1640745892996,"gmtModify":1640745892996,"author":{"id":"4097106422038760","authorId":"4097106422038760","name":"WinzWorld","avatar":"https://static.tigerbbs.com/f94c1af784ca5816fdcf61d311d21996","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4097106422038760","idStr":"4097106422038760"},"themes":[],"htmlText":"Thanks for sharing! 👍🏻","listText":"Thanks for sharing! 👍🏻","text":"Thanks for sharing! 👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/696418210","repostId":"1143687105","repostType":4,"repost":{"id":"1143687105","kind":"news","pubTimestamp":1640743835,"share":"https://www.laohu8.com/m/news/1143687105?lang=zh_CN&edition=full","pubTime":"2021-12-29 10:10","market":"us","language":"en","title":"APPS Stock Alert: 7 Things to Know About the Google Deal Goosing Digital Turbine Shares Today<blockquote>应用程序股票提醒：有关Google交易Goosing Digital Turbine今日股价上涨的7件事</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1143687105","media":"InvestorPlace","summary":"Shares of Digital Turbine(NASDAQ:APPS) slid today though the tech firm announced that it had agreed ","content":"<p><div> Shares of Digital Turbine(NASDAQ:APPS) slid today though the tech firm announced that it had agreed to undertake a “multi-year strategic partnership” with Alphabet’s (NASDAQ:GOOG, NASDAQ:GOOGL) Google...</p><p><blockquote><div>Digital Turbine（纳斯达克：APPS）的股价今天下跌，尽管该科技公司宣布已同意与Alphabet（纳斯达克：GOOG，纳斯达克：GOOGL）谷歌建立“多年战略合作伙伴关系”……</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/12/apps-stock-alert-7-things-to-know-about-the-google-deal-goosing-digital-turbine-shares-today/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/apps-stock-alert-7-things-to-know-about-the-google-deal-goosing-digital-turbine-shares-today/\">网页连接</a></blockquote></p><p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>APPS Stock Alert: 7 Things to Know About the Google Deal Goosing Digital Turbine Shares Today<blockquote>应用程序股票提醒：有关Google交易Goosing Digital Turbine今日股价上涨的7件事</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAPPS Stock Alert: 7 Things to Know About the Google Deal Goosing Digital Turbine Shares Today<blockquote>应用程序股票提醒：有关Google交易Goosing Digital Turbine今日股价上涨的7件事</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">InvestorPlace</strong><span class=\"h-time small\">2021-12-29 10:10</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> Shares of Digital Turbine(NASDAQ:APPS) slid today though the tech firm announced that it had agreed to undertake a “multi-year strategic partnership” with Alphabet’s (NASDAQ:GOOG, NASDAQ:GOOGL) Google...</p><p><blockquote><div>Digital Turbine（纳斯达克：APPS）的股价今天下跌，尽管该科技公司宣布已同意与Alphabet（纳斯达克：GOOG，纳斯达克：GOOGL）谷歌建立“多年战略合作伙伴关系”……</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/12/apps-stock-alert-7-things-to-know-about-the-google-deal-goosing-digital-turbine-shares-today/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/apps-stock-alert-7-things-to-know-about-the-google-deal-goosing-digital-turbine-shares-today/\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://investorplace.com/2021/12/apps-stock-alert-7-things-to-know-about-the-google-deal-goosing-digital-turbine-shares-today/\">InvestorPlace</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"APPS":"Digital Turbine Inc.","GOOG":"谷歌"},"source_url":"https://investorplace.com/2021/12/apps-stock-alert-7-things-to-know-about-the-google-deal-goosing-digital-turbine-shares-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143687105","content_text":"Shares of Digital Turbine(NASDAQ:APPS) slid today though the tech firm announced that it had agreed to undertake a “multi-year strategic partnership” with Alphabet’s (NASDAQ:GOOG, NASDAQ:GOOGL) Google. Digital Turbine’s technology enhances mobile ads and the monetization of mobile traffic. In early trading, APPS stock is down 1.73% to $62.34 amid much higher than normal volume.\nDigital Turbine did not disclose the financial terms of the alliance. However, here are seven things that we do know about the deal.\n\nDigital Turbine is going to collaborate with Google Cloud’s partner,SADA.\nDigital Turbine and SADA will attempt to quickly improve and geographically expand Google Cloud’s “enterprise and cloud solutions.”\nThe two companies will also seek to develop additional “growth and monetization” opportunities for Google’s “partners.”\nDigital Turbine will use Google’s “advanced cloud and enterprise infrastructure.”\nThe company will, for the first time, enhance the “mobile experiences” of overseas Android users.\nMore specifically, Digital Turbine will enable “app discovery for nearly a billion Android devices globally.”\nDigital Turbine will be supporting “mobile, TV and connected devices” that utilize Android.\n\nOther Things to Know About APPS Stock\nIn the last month, APPS stock has rallied over 20%. However, shares are still down nearly 30% from their late October peak. The stock now has a market capitalization of nearly $6.4 billion and is trading at a hefty, but not huge, trailing price-to-sales ratio of 7.45.\nAdditionally, institutional investors hold 75% of the shares. Among the largest institutional owners of the stock, as of Sept. 29, were Blackrock(NYSE:BLK) with a 10% stake,Wellington Management Group with a 6.55% stake,Vanguard Group with a 9.17% stake,State Street(NYSE:STT) with a 2.86% stake, and JPMorgan(NYSE:JPM), which owned 1.86% of the company.","news_type":1,"symbols_score_info":{"GOOG":0.9,"APPS":0.9}},"isVote":1,"tweetType":1,"viewCount":2480,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698332753,"gmtCreate":1640303160546,"gmtModify":1640303160546,"author":{"id":"4097106422038760","authorId":"4097106422038760","name":"WinzWorld","avatar":"https://static.tigerbbs.com/f94c1af784ca5816fdcf61d311d21996","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4097106422038760","idStr":"4097106422038760"},"themes":[],"htmlText":"Merry Christmas 🥂","listText":"Merry Christmas 🥂","text":"Merry Christmas 🥂","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698332753","repostId":"2193078140","repostType":2,"isVote":1,"tweetType":1,"viewCount":2184,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698333856,"gmtCreate":1640302633989,"gmtModify":1640302633989,"author":{"id":"4097106422038760","authorId":"4097106422038760","name":"WinzWorld","avatar":"https://static.tigerbbs.com/f94c1af784ca5816fdcf61d311d21996","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4097106422038760","idStr":"4097106422038760"},"themes":[],"htmlText":"Watching this space closely 😬","listText":"Watching this space closely 😬","text":"Watching this space closely 😬","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698333856","repostId":"1172289344","repostType":4,"repost":{"id":"1172289344","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640302012,"share":"https://www.laohu8.com/m/news/1172289344?lang=zh_CN&edition=full","pubTime":"2021-12-24 07:26","market":"us","language":"en","title":"How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?<blockquote>辉瑞的口服COVID-19药丸能带来多少收入？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1172289344","media":"Benzinga","summary":"Pfizer, Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for","content":"<p><b>Pfizer, Inc.</b>&nbsp;announced&nbsp;Wednesday its oral COVID-19 antiviral pill,&nbsp;<b>Paxlovid,</b>&nbsp;has been authorized for use by the U.S. Food and Drug Administration.</p><p><blockquote><b>辉瑞公司。</b>周三宣布推出口服COVID-19抗病毒药物，<b>帕克斯洛维德、</b>已被美国授权使用。食品和药物管理局。</blockquote></p><p> <b>The Pfizer Analysts:</b>SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.</p><p><blockquote><b>辉瑞分析师：</b>SVB Leerink分析师Geoffrey Porges给予辉瑞市场表现评级和52美元的目标价。</blockquote></p><p> BofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.</p><p><blockquote>美银证券分析师Geoff Meacham维持中性评级和59美元的目标价。</blockquote></p><p> <b>Broad Label, Increased Supply To Give Pfizer Dominant Market Position:</b>Pfizer received the nod for the oral COVID-19 treatment ahead of&nbsp;<b>Merck &amp; Co., Inc.</b>, which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.</p><p><blockquote><b>广泛的标签，增加供应使辉瑞占据主导市场地位：</b>辉瑞公司提前获得了口服COVID-19治疗的认可<b>默克公司。</b>Porges在一份报告中表示，该公司比辉瑞公司提前一个多月提交了molnupiravir的申请。</blockquote></p><p> The analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.</p><p><blockquote>该分析师认为，辉瑞明年Paxlovid的预期供应量增加至1.2亿个疗程意义重大。该分析师表示，该公司将销售和分销其中大部分课程，其收入将远远超过SVB Leerink目前预测的2022年Paxlovid销售额240亿美元和2023年330亿美元。</blockquote></p><p> Revenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.</p><p><blockquote>该分析师表示，2024年收入贡献将降至100亿美元。他补充说，预计2022-24年Paxlovid总销售额为670亿美元，远高于共识。</blockquote></p><p> The impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.</p><p><blockquote>Porges说，药物间相互作用对Paxlovid摄取的影响不大，因为清单上的许多药物可以在Paxlovid治疗的短期内暂停，而不会对患者产生重大影响。他补充说，可能被排除在Paxlovid使用之外的患者是那些患有严重肝或肾功能损害的患者以及那些HIV-1感染未得到控制的患者。</blockquote></p><p> The drug label also didn't&nbsp;preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.</p><p><blockquote>分析师表示，该药物标签也没有排除孕妇接受Paxlovid治疗，并且与默克公司的molnupiravir相比，其风险/益处相对良性，后者显示了动物的胚胎发育和胎儿生长风险。</blockquote></p><p> Paxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.</p><p><blockquote>Paxlovid比一些领先的抗体疗法具有更好的疗效，并且由于一些抗体疗法已经失去了针对奥密克戎病毒变异体的疗效，Paxlovid将是“对医生和患者来说非常有吸引力的选择”，Porges说。</blockquote></p><p> <b>Paxlovid Should Remain A Steady Contributor, BofA Says:</b>There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.</p><p><blockquote><b>美国银行表示，Paxlovid应该仍然是稳定的贡献者：</b>美国银行分析师米查姆表示，到2022年销售辉瑞生产的每一个疗程的Paxlovid应该没有问题。他补充说，生产和运输/收入确认之间的滞后时间意味着辉瑞不会在2022年确认每剂疫苗的收入。</blockquote></p><p> Longer-term, Paxlovid is likely to remain a steady contributor, the analyst said.</p><p><blockquote>分析师表示，从长远来看，Paxlovid可能仍然是一个稳定的贡献者。</blockquote></p><p> \"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.</p><p><blockquote>“我们预计突破性感染将在流行阶段定期继续，虽然疫苗和先前感染的基线免疫力水平将限制严重程度，但我们预计在高危个体中发生的新冠病例的治疗将成为标准护理，”米查姆说。</blockquote></p><p> Government entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.</p><p><blockquote>分析师表示，预计政府实体将储备默克的药物，因此初步销售可能会出现。他补充说，从长远来看，Paxlovid可能是首选药物。</blockquote></p><p> <b>Pfizer Price Action:</b>&nbsp;Pfizer shares closed&nbsp;lower 1.41% to $58.71 on&nbsp;Thursday.</p><p><blockquote><b>辉瑞价格走势：</b>辉瑞股价周四收盘下跌1.41%，至58.71美元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?<blockquote>辉瑞的口服COVID-19药丸能带来多少收入？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?<blockquote>辉瑞的口服COVID-19药丸能带来多少收入？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-24 07:26</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>Pfizer, Inc.</b>&nbsp;announced&nbsp;Wednesday its oral COVID-19 antiviral pill,&nbsp;<b>Paxlovid,</b>&nbsp;has been authorized for use by the U.S. Food and Drug Administration.</p><p><blockquote><b>辉瑞公司。</b>周三宣布推出口服COVID-19抗病毒药物，<b>帕克斯洛维德、</b>已被美国授权使用。食品和药物管理局。</blockquote></p><p> <b>The Pfizer Analysts:</b>SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.</p><p><blockquote><b>辉瑞分析师：</b>SVB Leerink分析师Geoffrey Porges给予辉瑞市场表现评级和52美元的目标价。</blockquote></p><p> BofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.</p><p><blockquote>美银证券分析师Geoff Meacham维持中性评级和59美元的目标价。</blockquote></p><p> <b>Broad Label, Increased Supply To Give Pfizer Dominant Market Position:</b>Pfizer received the nod for the oral COVID-19 treatment ahead of&nbsp;<b>Merck &amp; Co., Inc.</b>, which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.</p><p><blockquote><b>广泛的标签，增加供应使辉瑞占据主导市场地位：</b>辉瑞公司提前获得了口服COVID-19治疗的认可<b>默克公司。</b>Porges在一份报告中表示，该公司比辉瑞公司提前一个多月提交了molnupiravir的申请。</blockquote></p><p> The analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.</p><p><blockquote>该分析师认为，辉瑞明年Paxlovid的预期供应量增加至1.2亿个疗程意义重大。该分析师表示，该公司将销售和分销其中大部分课程，其收入将远远超过SVB Leerink目前预测的2022年Paxlovid销售额240亿美元和2023年330亿美元。</blockquote></p><p> Revenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.</p><p><blockquote>该分析师表示，2024年收入贡献将降至100亿美元。他补充说，预计2022-24年Paxlovid总销售额为670亿美元，远高于共识。</blockquote></p><p> The impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.</p><p><blockquote>Porges说，药物间相互作用对Paxlovid摄取的影响不大，因为清单上的许多药物可以在Paxlovid治疗的短期内暂停，而不会对患者产生重大影响。他补充说，可能被排除在Paxlovid使用之外的患者是那些患有严重肝或肾功能损害的患者以及那些HIV-1感染未得到控制的患者。</blockquote></p><p> The drug label also didn't&nbsp;preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.</p><p><blockquote>分析师表示，该药物标签也没有排除孕妇接受Paxlovid治疗，并且与默克公司的molnupiravir相比，其风险/益处相对良性，后者显示了动物的胚胎发育和胎儿生长风险。</blockquote></p><p> Paxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.</p><p><blockquote>Paxlovid比一些领先的抗体疗法具有更好的疗效，并且由于一些抗体疗法已经失去了针对奥密克戎病毒变异体的疗效，Paxlovid将是“对医生和患者来说非常有吸引力的选择”，Porges说。</blockquote></p><p> <b>Paxlovid Should Remain A Steady Contributor, BofA Says:</b>There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.</p><p><blockquote><b>美国银行表示，Paxlovid应该仍然是稳定的贡献者：</b>美国银行分析师米查姆表示，到2022年销售辉瑞生产的每一个疗程的Paxlovid应该没有问题。他补充说，生产和运输/收入确认之间的滞后时间意味着辉瑞不会在2022年确认每剂疫苗的收入。</blockquote></p><p> Longer-term, Paxlovid is likely to remain a steady contributor, the analyst said.</p><p><blockquote>分析师表示，从长远来看，Paxlovid可能仍然是一个稳定的贡献者。</blockquote></p><p> \"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.</p><p><blockquote>“我们预计突破性感染将在流行阶段定期继续，虽然疫苗和先前感染的基线免疫力水平将限制严重程度，但我们预计在高危个体中发生的新冠病例的治疗将成为标准护理，”米查姆说。</blockquote></p><p> Government entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.</p><p><blockquote>分析师表示，预计政府实体将储备默克的药物，因此初步销售可能会出现。他补充说，从长远来看，Paxlovid可能是首选药物。</blockquote></p><p> <b>Pfizer Price Action:</b>&nbsp;Pfizer shares closed&nbsp;lower 1.41% to $58.71 on&nbsp;Thursday.</p><p><blockquote><b>辉瑞价格走势：</b>辉瑞股价周四收盘下跌1.41%，至58.71美元。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172289344","content_text":"Pfizer, Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for use by the U.S. Food and Drug Administration.\nThe Pfizer Analysts:SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.\nBofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.\nBroad Label, Increased Supply To Give Pfizer Dominant Market Position:Pfizer received the nod for the oral COVID-19 treatment ahead of Merck & Co., Inc., which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.\nThe analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.\nRevenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.\nThe impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.\nThe drug label also didn't preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.\nPaxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.\nPaxlovid Should Remain A Steady Contributor, BofA Says:There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.\nLonger-term, Paxlovid is likely to remain a steady contributor, the analyst said.\n\"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.\nGovernment entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.\nPfizer Price Action: Pfizer shares closed lower 1.41% to $58.71 on Thursday.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2141,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698339746,"gmtCreate":1640302554512,"gmtModify":1640302554512,"author":{"id":"4097106422038760","authorId":"4097106422038760","name":"WinzWorld","avatar":"https://static.tigerbbs.com/f94c1af784ca5816fdcf61d311d21996","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4097106422038760","idStr":"4097106422038760"},"themes":[],"htmlText":"The risk of delisting is really an issue for me...not sure if should take the risk and exit as soon as the price hits my target 🤔","listText":"The risk of delisting is really an issue for me...not sure if should take the risk and exit as soon as the price hits my target 🤔","text":"The risk of delisting is really an issue for me...not sure if should take the risk and exit as soon as the price hits my target 🤔","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":6,"repostSize":0,"link":"https://laohu8.com/post/698339746","repostId":"1169545714","repostType":4,"repost":{"id":"1169545714","kind":"news","pubTimestamp":1640272530,"share":"https://www.laohu8.com/m/news/1169545714?lang=zh_CN&edition=full","pubTime":"2021-12-23 23:15","market":"us","language":"en","title":"Nio is on watch with attractive buying opportunity called out by Deutsche Bank<blockquote>德意志银行呼吁蔚来有吸引力的买入机会，受到关注</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1169545714","media":"seekingalpha","summary":"Niois a new addition to the fresh money list at Deutsche Bank on what it calls an attractive buying opportunity heading into the new year.Analyst Edison Yu: \"With the stock having underperformed materially in recent months, we see a great entry point setting up for a pivotal 2022. Investor sentiment has been lackluster due to lack of new vehicles and supply chain constraints, and most recently, the heightened US delisting risk. We believe these headwinds can all reverse in the coming 12 months w","content":"<p>Nio(NYSE:NIO)is a new addition to the fresh money list at Deutsche Bank on what it calls an attractive&nbsp;buying opportunity heading into the new year.</p><p><blockquote>蔚来（纽约证券交易所股票代码：蔚来）是德意志银行新鲜资金名单上的新成员，该银行认为这是进入新的一年的一个有吸引力的买入机会。</blockquote></p><p> Analyst Edison Yu: \"With the stock having underperformed materially in recent months, we see a great entry point setting up for a pivotal 2022. Investor sentiment has been lackluster due to lack of new vehicles and supply chain constraints, and most recently, the heightened US delisting risk. We believe these headwinds can all reverse in the coming 12 months with NIO launching 3 new models over the next 12 months and boosting manufacturing capacity from 120k to 600k.\"</p><p><blockquote>分析师Edison Yu：“由于该股近几个月表现严重不佳，我们认为关键的2022年将迎来一个绝佳的切入点。由于缺乏新车和供应链限制，投资者情绪一直低迷，最近美国退市风险加剧。我们相信，随着蔚来在未来12个月内推出3款新车型，并将产能从12万辆提高到60万辆，这些不利因素都可能在未来12个月内扭转。”</blockquote></p><p> Yu points to a big year for the ET5 model in particular.</p><p><blockquote>Yu特别指出ET5车型今年是重要的一年。</blockquote></p><p> Deutsche Bank keeps a Buy rating on the Chinese EV stock.</p><p><blockquote>德意志银行维持对中国电动汽车股票的买入评级。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nio is on watch with attractive buying opportunity called out by Deutsche Bank<blockquote>德意志银行呼吁蔚来有吸引力的买入机会，受到关注</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNio is on watch with attractive buying opportunity called out by Deutsche Bank<blockquote>德意志银行呼吁蔚来有吸引力的买入机会，受到关注</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">seekingalpha</strong><span class=\"h-time small\">2021-12-23 23:15</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Nio(NYSE:NIO)is a new addition to the fresh money list at Deutsche Bank on what it calls an attractive&nbsp;buying opportunity heading into the new year.</p><p><blockquote>蔚来（纽约证券交易所股票代码：蔚来）是德意志银行新鲜资金名单上的新成员，该银行认为这是进入新的一年的一个有吸引力的买入机会。</blockquote></p><p> Analyst Edison Yu: \"With the stock having underperformed materially in recent months, we see a great entry point setting up for a pivotal 2022. Investor sentiment has been lackluster due to lack of new vehicles and supply chain constraints, and most recently, the heightened US delisting risk. We believe these headwinds can all reverse in the coming 12 months with NIO launching 3 new models over the next 12 months and boosting manufacturing capacity from 120k to 600k.\"</p><p><blockquote>分析师Edison Yu：“由于该股近几个月表现严重不佳，我们认为关键的2022年将迎来一个绝佳的切入点。由于缺乏新车和供应链限制，投资者情绪一直低迷，最近美国退市风险加剧。我们相信，随着蔚来在未来12个月内推出3款新车型，并将产能从12万辆提高到60万辆，这些不利因素都可能在未来12个月内扭转。”</blockquote></p><p> Yu points to a big year for the ET5 model in particular.</p><p><blockquote>Yu特别指出ET5车型今年是重要的一年。</blockquote></p><p> Deutsche Bank keeps a Buy rating on the Chinese EV stock.</p><p><blockquote>德意志银行维持对中国电动汽车股票的买入评级。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3783031-nio-is-on-watch-with-attractive-buying-opportunity-called-out-by-deutsche-bank\">seekingalpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"source_url":"https://seekingalpha.com/news/3783031-nio-is-on-watch-with-attractive-buying-opportunity-called-out-by-deutsche-bank","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169545714","content_text":"Nio(NYSE:NIO)is a new addition to the fresh money list at Deutsche Bank on what it calls an attractive buying opportunity heading into the new year.\nAnalyst Edison Yu: \"With the stock having underperformed materially in recent months, we see a great entry point setting up for a pivotal 2022. Investor sentiment has been lackluster due to lack of new vehicles and supply chain constraints, and most recently, the heightened US delisting risk. We believe these headwinds can all reverse in the coming 12 months with NIO launching 3 new models over the next 12 months and boosting manufacturing capacity from 120k to 600k.\"\nYu points to a big year for the ET5 model in particular.\nDeutsche Bank keeps a Buy rating on the Chinese EV stock.","news_type":1,"symbols_score_info":{"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":3142,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":698339746,"gmtCreate":1640302554512,"gmtModify":1640302554512,"author":{"id":"4097106422038760","authorId":"4097106422038760","name":"WinzWorld","avatar":"https://static.tigerbbs.com/f94c1af784ca5816fdcf61d311d21996","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4097106422038760","idStr":"4097106422038760"},"themes":[],"htmlText":"The risk of delisting is really an issue for me...not sure if should take the risk and exit as soon as the price hits my target 🤔","listText":"The risk of delisting is really an issue for me...not sure if should take the risk and exit as soon as the price hits my target 🤔","text":"The risk of delisting is really an issue for me...not sure if should take the risk and exit as soon as the price hits my target 🤔","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":6,"repostSize":0,"link":"https://laohu8.com/post/698339746","repostId":"1169545714","repostType":4,"repost":{"id":"1169545714","kind":"news","pubTimestamp":1640272530,"share":"https://www.laohu8.com/m/news/1169545714?lang=zh_CN&edition=full","pubTime":"2021-12-23 23:15","market":"us","language":"en","title":"Nio is on watch with attractive buying opportunity called out by Deutsche Bank<blockquote>德意志银行呼吁蔚来有吸引力的买入机会，受到关注</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1169545714","media":"seekingalpha","summary":"Niois a new addition to the fresh money list at Deutsche Bank on what it calls an attractive buying opportunity heading into the new year.Analyst Edison Yu: \"With the stock having underperformed materially in recent months, we see a great entry point setting up for a pivotal 2022. Investor sentiment has been lackluster due to lack of new vehicles and supply chain constraints, and most recently, the heightened US delisting risk. We believe these headwinds can all reverse in the coming 12 months w","content":"<p>Nio(NYSE:NIO)is a new addition to the fresh money list at Deutsche Bank on what it calls an attractive&nbsp;buying opportunity heading into the new year.</p><p><blockquote>蔚来（纽约证券交易所股票代码：蔚来）是德意志银行新鲜资金名单上的新成员，该银行认为这是进入新的一年的一个有吸引力的买入机会。</blockquote></p><p> Analyst Edison Yu: \"With the stock having underperformed materially in recent months, we see a great entry point setting up for a pivotal 2022. Investor sentiment has been lackluster due to lack of new vehicles and supply chain constraints, and most recently, the heightened US delisting risk. We believe these headwinds can all reverse in the coming 12 months with NIO launching 3 new models over the next 12 months and boosting manufacturing capacity from 120k to 600k.\"</p><p><blockquote>分析师Edison Yu：“由于该股近几个月表现严重不佳，我们认为关键的2022年将迎来一个绝佳的切入点。由于缺乏新车和供应链限制，投资者情绪一直低迷，最近美国退市风险加剧。我们相信，随着蔚来在未来12个月内推出3款新车型，并将产能从12万辆提高到60万辆，这些不利因素都可能在未来12个月内扭转。”</blockquote></p><p> Yu points to a big year for the ET5 model in particular.</p><p><blockquote>Yu特别指出ET5车型今年是重要的一年。</blockquote></p><p> Deutsche Bank keeps a Buy rating on the Chinese EV stock.</p><p><blockquote>德意志银行维持对中国电动汽车股票的买入评级。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nio is on watch with attractive buying opportunity called out by Deutsche Bank<blockquote>德意志银行呼吁蔚来有吸引力的买入机会，受到关注</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNio is on watch with attractive buying opportunity called out by Deutsche Bank<blockquote>德意志银行呼吁蔚来有吸引力的买入机会，受到关注</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">seekingalpha</strong><span class=\"h-time small\">2021-12-23 23:15</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Nio(NYSE:NIO)is a new addition to the fresh money list at Deutsche Bank on what it calls an attractive&nbsp;buying opportunity heading into the new year.</p><p><blockquote>蔚来（纽约证券交易所股票代码：蔚来）是德意志银行新鲜资金名单上的新成员，该银行认为这是进入新的一年的一个有吸引力的买入机会。</blockquote></p><p> Analyst Edison Yu: \"With the stock having underperformed materially in recent months, we see a great entry point setting up for a pivotal 2022. Investor sentiment has been lackluster due to lack of new vehicles and supply chain constraints, and most recently, the heightened US delisting risk. We believe these headwinds can all reverse in the coming 12 months with NIO launching 3 new models over the next 12 months and boosting manufacturing capacity from 120k to 600k.\"</p><p><blockquote>分析师Edison Yu：“由于该股近几个月表现严重不佳，我们认为关键的2022年将迎来一个绝佳的切入点。由于缺乏新车和供应链限制，投资者情绪一直低迷，最近美国退市风险加剧。我们相信，随着蔚来在未来12个月内推出3款新车型，并将产能从12万辆提高到60万辆，这些不利因素都可能在未来12个月内扭转。”</blockquote></p><p> Yu points to a big year for the ET5 model in particular.</p><p><blockquote>Yu特别指出ET5车型今年是重要的一年。</blockquote></p><p> Deutsche Bank keeps a Buy rating on the Chinese EV stock.</p><p><blockquote>德意志银行维持对中国电动汽车股票的买入评级。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3783031-nio-is-on-watch-with-attractive-buying-opportunity-called-out-by-deutsche-bank\">seekingalpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"source_url":"https://seekingalpha.com/news/3783031-nio-is-on-watch-with-attractive-buying-opportunity-called-out-by-deutsche-bank","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169545714","content_text":"Nio(NYSE:NIO)is a new addition to the fresh money list at Deutsche Bank on what it calls an attractive buying opportunity heading into the new year.\nAnalyst Edison Yu: \"With the stock having underperformed materially in recent months, we see a great entry point setting up for a pivotal 2022. Investor sentiment has been lackluster due to lack of new vehicles and supply chain constraints, and most recently, the heightened US delisting risk. We believe these headwinds can all reverse in the coming 12 months with NIO launching 3 new models over the next 12 months and boosting manufacturing capacity from 120k to 600k.\"\nYu points to a big year for the ET5 model in particular.\nDeutsche Bank keeps a Buy rating on the Chinese EV stock.","news_type":1,"symbols_score_info":{"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":3142,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698332753,"gmtCreate":1640303160546,"gmtModify":1640303160546,"author":{"id":"4097106422038760","authorId":"4097106422038760","name":"WinzWorld","avatar":"https://static.tigerbbs.com/f94c1af784ca5816fdcf61d311d21996","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4097106422038760","idStr":"4097106422038760"},"themes":[],"htmlText":"Merry Christmas 🥂","listText":"Merry Christmas 🥂","text":"Merry Christmas 🥂","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698332753","repostId":"2193078140","repostType":2,"isVote":1,"tweetType":1,"viewCount":2184,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696418210,"gmtCreate":1640745892996,"gmtModify":1640745892996,"author":{"id":"4097106422038760","authorId":"4097106422038760","name":"WinzWorld","avatar":"https://static.tigerbbs.com/f94c1af784ca5816fdcf61d311d21996","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4097106422038760","idStr":"4097106422038760"},"themes":[],"htmlText":"Thanks for sharing! 👍🏻","listText":"Thanks for sharing! 👍🏻","text":"Thanks for sharing! 👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/696418210","repostId":"1143687105","repostType":4,"repost":{"id":"1143687105","kind":"news","pubTimestamp":1640743835,"share":"https://www.laohu8.com/m/news/1143687105?lang=zh_CN&edition=full","pubTime":"2021-12-29 10:10","market":"us","language":"en","title":"APPS Stock Alert: 7 Things to Know About the Google Deal Goosing Digital Turbine Shares Today<blockquote>应用程序股票提醒：有关Google交易Goosing Digital Turbine今日股价上涨的7件事</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1143687105","media":"InvestorPlace","summary":"Shares of Digital Turbine(NASDAQ:APPS) slid today though the tech firm announced that it had agreed ","content":"<p><div> Shares of Digital Turbine(NASDAQ:APPS) slid today though the tech firm announced that it had agreed to undertake a “multi-year strategic partnership” with Alphabet’s (NASDAQ:GOOG, NASDAQ:GOOGL) Google...</p><p><blockquote><div>Digital Turbine（纳斯达克：APPS）的股价今天下跌，尽管该科技公司宣布已同意与Alphabet（纳斯达克：GOOG，纳斯达克：GOOGL）谷歌建立“多年战略合作伙伴关系”……</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/12/apps-stock-alert-7-things-to-know-about-the-google-deal-goosing-digital-turbine-shares-today/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/apps-stock-alert-7-things-to-know-about-the-google-deal-goosing-digital-turbine-shares-today/\">网页连接</a></blockquote></p><p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>APPS Stock Alert: 7 Things to Know About the Google Deal Goosing Digital Turbine Shares Today<blockquote>应用程序股票提醒：有关Google交易Goosing Digital Turbine今日股价上涨的7件事</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAPPS Stock Alert: 7 Things to Know About the Google Deal Goosing Digital Turbine Shares Today<blockquote>应用程序股票提醒：有关Google交易Goosing Digital Turbine今日股价上涨的7件事</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">InvestorPlace</strong><span class=\"h-time small\">2021-12-29 10:10</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> Shares of Digital Turbine(NASDAQ:APPS) slid today though the tech firm announced that it had agreed to undertake a “multi-year strategic partnership” with Alphabet’s (NASDAQ:GOOG, NASDAQ:GOOGL) Google...</p><p><blockquote><div>Digital Turbine（纳斯达克：APPS）的股价今天下跌，尽管该科技公司宣布已同意与Alphabet（纳斯达克：GOOG，纳斯达克：GOOGL）谷歌建立“多年战略合作伙伴关系”……</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/12/apps-stock-alert-7-things-to-know-about-the-google-deal-goosing-digital-turbine-shares-today/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/apps-stock-alert-7-things-to-know-about-the-google-deal-goosing-digital-turbine-shares-today/\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://investorplace.com/2021/12/apps-stock-alert-7-things-to-know-about-the-google-deal-goosing-digital-turbine-shares-today/\">InvestorPlace</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"APPS":"Digital Turbine Inc.","GOOG":"谷歌"},"source_url":"https://investorplace.com/2021/12/apps-stock-alert-7-things-to-know-about-the-google-deal-goosing-digital-turbine-shares-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143687105","content_text":"Shares of Digital Turbine(NASDAQ:APPS) slid today though the tech firm announced that it had agreed to undertake a “multi-year strategic partnership” with Alphabet’s (NASDAQ:GOOG, NASDAQ:GOOGL) Google. Digital Turbine’s technology enhances mobile ads and the monetization of mobile traffic. In early trading, APPS stock is down 1.73% to $62.34 amid much higher than normal volume.\nDigital Turbine did not disclose the financial terms of the alliance. However, here are seven things that we do know about the deal.\n\nDigital Turbine is going to collaborate with Google Cloud’s partner,SADA.\nDigital Turbine and SADA will attempt to quickly improve and geographically expand Google Cloud’s “enterprise and cloud solutions.”\nThe two companies will also seek to develop additional “growth and monetization” opportunities for Google’s “partners.”\nDigital Turbine will use Google’s “advanced cloud and enterprise infrastructure.”\nThe company will, for the first time, enhance the “mobile experiences” of overseas Android users.\nMore specifically, Digital Turbine will enable “app discovery for nearly a billion Android devices globally.”\nDigital Turbine will be supporting “mobile, TV and connected devices” that utilize Android.\n\nOther Things to Know About APPS Stock\nIn the last month, APPS stock has rallied over 20%. However, shares are still down nearly 30% from their late October peak. The stock now has a market capitalization of nearly $6.4 billion and is trading at a hefty, but not huge, trailing price-to-sales ratio of 7.45.\nAdditionally, institutional investors hold 75% of the shares. Among the largest institutional owners of the stock, as of Sept. 29, were Blackrock(NYSE:BLK) with a 10% stake,Wellington Management Group with a 6.55% stake,Vanguard Group with a 9.17% stake,State Street(NYSE:STT) with a 2.86% stake, and JPMorgan(NYSE:JPM), which owned 1.86% of the company.","news_type":1,"symbols_score_info":{"GOOG":0.9,"APPS":0.9}},"isVote":1,"tweetType":1,"viewCount":2480,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698333856,"gmtCreate":1640302633989,"gmtModify":1640302633989,"author":{"id":"4097106422038760","authorId":"4097106422038760","name":"WinzWorld","avatar":"https://static.tigerbbs.com/f94c1af784ca5816fdcf61d311d21996","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4097106422038760","idStr":"4097106422038760"},"themes":[],"htmlText":"Watching this space closely 😬","listText":"Watching this space closely 😬","text":"Watching this space closely 😬","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698333856","repostId":"1172289344","repostType":4,"repost":{"id":"1172289344","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640302012,"share":"https://www.laohu8.com/m/news/1172289344?lang=zh_CN&edition=full","pubTime":"2021-12-24 07:26","market":"us","language":"en","title":"How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?<blockquote>辉瑞的口服COVID-19药丸能带来多少收入？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1172289344","media":"Benzinga","summary":"Pfizer, Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for","content":"<p><b>Pfizer, Inc.</b>&nbsp;announced&nbsp;Wednesday its oral COVID-19 antiviral pill,&nbsp;<b>Paxlovid,</b>&nbsp;has been authorized for use by the U.S. Food and Drug Administration.</p><p><blockquote><b>辉瑞公司。</b>周三宣布推出口服COVID-19抗病毒药物，<b>帕克斯洛维德、</b>已被美国授权使用。食品和药物管理局。</blockquote></p><p> <b>The Pfizer Analysts:</b>SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.</p><p><blockquote><b>辉瑞分析师：</b>SVB Leerink分析师Geoffrey Porges给予辉瑞市场表现评级和52美元的目标价。</blockquote></p><p> BofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.</p><p><blockquote>美银证券分析师Geoff Meacham维持中性评级和59美元的目标价。</blockquote></p><p> <b>Broad Label, Increased Supply To Give Pfizer Dominant Market Position:</b>Pfizer received the nod for the oral COVID-19 treatment ahead of&nbsp;<b>Merck &amp; Co., Inc.</b>, which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.</p><p><blockquote><b>广泛的标签，增加供应使辉瑞占据主导市场地位：</b>辉瑞公司提前获得了口服COVID-19治疗的认可<b>默克公司。</b>Porges在一份报告中表示，该公司比辉瑞公司提前一个多月提交了molnupiravir的申请。</blockquote></p><p> The analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.</p><p><blockquote>该分析师认为，辉瑞明年Paxlovid的预期供应量增加至1.2亿个疗程意义重大。该分析师表示，该公司将销售和分销其中大部分课程，其收入将远远超过SVB Leerink目前预测的2022年Paxlovid销售额240亿美元和2023年330亿美元。</blockquote></p><p> Revenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.</p><p><blockquote>该分析师表示，2024年收入贡献将降至100亿美元。他补充说，预计2022-24年Paxlovid总销售额为670亿美元，远高于共识。</blockquote></p><p> The impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.</p><p><blockquote>Porges说，药物间相互作用对Paxlovid摄取的影响不大，因为清单上的许多药物可以在Paxlovid治疗的短期内暂停，而不会对患者产生重大影响。他补充说，可能被排除在Paxlovid使用之外的患者是那些患有严重肝或肾功能损害的患者以及那些HIV-1感染未得到控制的患者。</blockquote></p><p> The drug label also didn't&nbsp;preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.</p><p><blockquote>分析师表示，该药物标签也没有排除孕妇接受Paxlovid治疗，并且与默克公司的molnupiravir相比，其风险/益处相对良性，后者显示了动物的胚胎发育和胎儿生长风险。</blockquote></p><p> Paxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.</p><p><blockquote>Paxlovid比一些领先的抗体疗法具有更好的疗效，并且由于一些抗体疗法已经失去了针对奥密克戎病毒变异体的疗效，Paxlovid将是“对医生和患者来说非常有吸引力的选择”，Porges说。</blockquote></p><p> <b>Paxlovid Should Remain A Steady Contributor, BofA Says:</b>There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.</p><p><blockquote><b>美国银行表示，Paxlovid应该仍然是稳定的贡献者：</b>美国银行分析师米查姆表示，到2022年销售辉瑞生产的每一个疗程的Paxlovid应该没有问题。他补充说，生产和运输/收入确认之间的滞后时间意味着辉瑞不会在2022年确认每剂疫苗的收入。</blockquote></p><p> Longer-term, Paxlovid is likely to remain a steady contributor, the analyst said.</p><p><blockquote>分析师表示，从长远来看，Paxlovid可能仍然是一个稳定的贡献者。</blockquote></p><p> \"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.</p><p><blockquote>“我们预计突破性感染将在流行阶段定期继续，虽然疫苗和先前感染的基线免疫力水平将限制严重程度，但我们预计在高危个体中发生的新冠病例的治疗将成为标准护理，”米查姆说。</blockquote></p><p> Government entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.</p><p><blockquote>分析师表示，预计政府实体将储备默克的药物，因此初步销售可能会出现。他补充说，从长远来看，Paxlovid可能是首选药物。</blockquote></p><p> <b>Pfizer Price Action:</b>&nbsp;Pfizer shares closed&nbsp;lower 1.41% to $58.71 on&nbsp;Thursday.</p><p><blockquote><b>辉瑞价格走势：</b>辉瑞股价周四收盘下跌1.41%，至58.71美元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?<blockquote>辉瑞的口服COVID-19药丸能带来多少收入？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?<blockquote>辉瑞的口服COVID-19药丸能带来多少收入？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-24 07:26</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>Pfizer, Inc.</b>&nbsp;announced&nbsp;Wednesday its oral COVID-19 antiviral pill,&nbsp;<b>Paxlovid,</b>&nbsp;has been authorized for use by the U.S. Food and Drug Administration.</p><p><blockquote><b>辉瑞公司。</b>周三宣布推出口服COVID-19抗病毒药物，<b>帕克斯洛维德、</b>已被美国授权使用。食品和药物管理局。</blockquote></p><p> <b>The Pfizer Analysts:</b>SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.</p><p><blockquote><b>辉瑞分析师：</b>SVB Leerink分析师Geoffrey Porges给予辉瑞市场表现评级和52美元的目标价。</blockquote></p><p> BofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.</p><p><blockquote>美银证券分析师Geoff Meacham维持中性评级和59美元的目标价。</blockquote></p><p> <b>Broad Label, Increased Supply To Give Pfizer Dominant Market Position:</b>Pfizer received the nod for the oral COVID-19 treatment ahead of&nbsp;<b>Merck &amp; Co., Inc.</b>, which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.</p><p><blockquote><b>广泛的标签，增加供应使辉瑞占据主导市场地位：</b>辉瑞公司提前获得了口服COVID-19治疗的认可<b>默克公司。</b>Porges在一份报告中表示，该公司比辉瑞公司提前一个多月提交了molnupiravir的申请。</blockquote></p><p> The analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.</p><p><blockquote>该分析师认为，辉瑞明年Paxlovid的预期供应量增加至1.2亿个疗程意义重大。该分析师表示，该公司将销售和分销其中大部分课程，其收入将远远超过SVB Leerink目前预测的2022年Paxlovid销售额240亿美元和2023年330亿美元。</blockquote></p><p> Revenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.</p><p><blockquote>该分析师表示，2024年收入贡献将降至100亿美元。他补充说，预计2022-24年Paxlovid总销售额为670亿美元，远高于共识。</blockquote></p><p> The impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.</p><p><blockquote>Porges说，药物间相互作用对Paxlovid摄取的影响不大，因为清单上的许多药物可以在Paxlovid治疗的短期内暂停，而不会对患者产生重大影响。他补充说，可能被排除在Paxlovid使用之外的患者是那些患有严重肝或肾功能损害的患者以及那些HIV-1感染未得到控制的患者。</blockquote></p><p> The drug label also didn't&nbsp;preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.</p><p><blockquote>分析师表示，该药物标签也没有排除孕妇接受Paxlovid治疗，并且与默克公司的molnupiravir相比，其风险/益处相对良性，后者显示了动物的胚胎发育和胎儿生长风险。</blockquote></p><p> Paxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.</p><p><blockquote>Paxlovid比一些领先的抗体疗法具有更好的疗效，并且由于一些抗体疗法已经失去了针对奥密克戎病毒变异体的疗效，Paxlovid将是“对医生和患者来说非常有吸引力的选择”，Porges说。</blockquote></p><p> <b>Paxlovid Should Remain A Steady Contributor, BofA Says:</b>There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.</p><p><blockquote><b>美国银行表示，Paxlovid应该仍然是稳定的贡献者：</b>美国银行分析师米查姆表示，到2022年销售辉瑞生产的每一个疗程的Paxlovid应该没有问题。他补充说，生产和运输/收入确认之间的滞后时间意味着辉瑞不会在2022年确认每剂疫苗的收入。</blockquote></p><p> Longer-term, Paxlovid is likely to remain a steady contributor, the analyst said.</p><p><blockquote>分析师表示，从长远来看，Paxlovid可能仍然是一个稳定的贡献者。</blockquote></p><p> \"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.</p><p><blockquote>“我们预计突破性感染将在流行阶段定期继续，虽然疫苗和先前感染的基线免疫力水平将限制严重程度，但我们预计在高危个体中发生的新冠病例的治疗将成为标准护理，”米查姆说。</blockquote></p><p> Government entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.</p><p><blockquote>分析师表示，预计政府实体将储备默克的药物，因此初步销售可能会出现。他补充说，从长远来看，Paxlovid可能是首选药物。</blockquote></p><p> <b>Pfizer Price Action:</b>&nbsp;Pfizer shares closed&nbsp;lower 1.41% to $58.71 on&nbsp;Thursday.</p><p><blockquote><b>辉瑞价格走势：</b>辉瑞股价周四收盘下跌1.41%，至58.71美元。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172289344","content_text":"Pfizer, Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for use by the U.S. Food and Drug Administration.\nThe Pfizer Analysts:SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.\nBofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.\nBroad Label, Increased Supply To Give Pfizer Dominant Market Position:Pfizer received the nod for the oral COVID-19 treatment ahead of Merck & Co., Inc., which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.\nThe analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.\nRevenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.\nThe impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.\nThe drug label also didn't preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.\nPaxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.\nPaxlovid Should Remain A Steady Contributor, BofA Says:There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.\nLonger-term, Paxlovid is likely to remain a steady contributor, the analyst said.\n\"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.\nGovernment entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.\nPfizer Price Action: Pfizer shares closed lower 1.41% to $58.71 on Thursday.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2141,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}